{
    "nct_id": "NCT03898791",
    "official_title": "Phase 1b Study of LY3295668 Erbumine Monotherapy in Patients With Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer",
    "inclusion_criteria": "* Have histological or cytological evidence of a diagnosis of platinum sensitive small cell lung cancer that is extensive stage.\n* Have adequate organ function.\n* Have a performance status (PS) of â‰¤1 on the Eastern Cooperative Oncology Group (ECOG) scale.\n* Have discontinued previous treatments for cancer.\n* Are able to swallow capsules.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Currently enrolled in a clinical study.\n* Have a serious concomitant systemic disorder.\n* Have a symptomatic human immunodeficiency virus infection or symptomatic activated/reactivated hepatitis B or C.\n* Have a significant cardiac condition.\n* Have previously received an aurora kinase inhibitor.",
    "miscellaneous_criteria": ""
}